Fredun Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended December 31, 2025, demonstrating robust financial performance. The Board of Directors approved these results at their meeting held on February 9, 2026, in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Overview

The pharmaceutical company delivered strong operational results during the third quarter. The financial statements were prepared in accordance with Indian Accounting Standards (Ind AS) and subjected to limited review by statutory auditors R.H. Nisar & Co.

Standalone Financial Results

Nine Months Performance

For the nine months ended December 31, 2025, the company reported net sales of ₹42,291.45 lakhs compared to ₹28,626.86 lakhs in the corresponding period of the previous year, representing a growth of 47.73%. Net profit for the nine-month period stood at ₹2,697.62 lakhs against ₹1,373.58 lakhs in the previous year, marking a 96.37% increase.

Consolidated Results

The consolidated financial results include the performance of subsidiaries Fredun Retail Private Limited, One Pet Stop Private Limited, and Wagr Retail Private Limited. Consolidated net sales for Q3 FY26 were ₹15,992.63 lakhs with a net profit of ₹1,047.80 lakhs.

Key Financial Metrics

Earnings Conference Call Recording Available

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has made available the audio recording of the earnings conference call held on February 12, 2026. The conference call discussed the unaudited financial results for the quarter ended December 31, 2025.

Conference Call Details

Board Meeting and Regulatory Compliance

The Board Meeting commenced at 11:00 AM and concluded at 1:50 PM on February 9, 2026. The company has fulfilled its regulatory obligations under SEBI regulations, with Managing Director Fredun Nariman Medhora (DIN: 01745348) signing the compliance documents.

Auditor's Review

Statutory auditors R.H. Nisar & Co. (Firm Registration Number: 120895W) conducted a limited review of the unaudited financial results. The auditors issued an unmodified conclusion, confirming that the financial statements comply with Indian Accounting Standards and SEBI disclosure requirements.

The company operates in a single business segment of "Pharmaceutical and Healthcare," with manufacturing facilities located at Zorabian Industrial Complex, Vevoor, Palghar, and registered office at Urmi Estate, Mumbai.

Fredun Pharmaceuticals Limited has formally notified the stock exchanges about its upcoming board meeting scheduled for February 9, 2026. The pharmaceutical company will present its third quarter financial performance for the period ended December 31, 2025, marking a significant milestone in its fiscal year reporting cycle.

Board Meeting Details

The company has issued prior intimation under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, confirming the board meeting agenda and timeline.

Trading Window Restrictions

In accordance with Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, Fredun Pharmaceuticals has implemented mandatory trading restrictions. The trading window for dealing in the company's securities will remain closed for all restricted personnel until 48 hours after the financial results declaration.

The trading window closure affects:

• Company Directors
• Officers and Key Managerial Personnel
• Designated Employees

Regulatory Compliance and Disclosure

The intimation has been filed with BSE Limited and is available on multiple platforms for stakeholder access. The company maintains transparency through proper disclosure channels, with the notification accessible on both the company's official website at www.fredungroup.com and BSE Limited's website at www.bseindia.com .

The formal communication was signed by Fredun Nariman Medhora, Managing Director (DIN: 01745348), ensuring proper authorization and compliance with corporate governance requirements. This scheduled board meeting represents the company's commitment to timely financial reporting and regulatory adherence in the pharmaceutical sector.